A randomised study of two schedules of radiotherapy or chemotherapy in elderly patients with high grade glioma

Submission date	Recruitment status No longer recruiting	Prospectively registered		
12/02/2010		Protocol		
Registration date	Overall study status	Statistical analysis plan		
03/03/2010	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
30/10/2012	Cancer			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Annika Malmström

Contact details

Unit of Advanced Palliative Home Care (Linköpings Avancerad Hemsjukvård [LAH]) Linköping Regional Hospital (Regionsjukhuset i Linköping) Linköping Sweden 581 85

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title

A multicentre randomised active controlled study comparing two schedules of radiotherapy or chemotherapy in elderly patients with high grade glioma

Acronym

Temodal elderly

Study objectives

To compare conventional radiotherapy (RT) (2 Gy up to 60 Gy) to short term RT (3.4 Gy up to 34 Gy) or chemotherapy alone after surgery or biopsy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Linköping Ethics Committee approved in April 1999 (ref: Dnr 99086)

Study design

Multicentre open label randomised active controlled parallel group trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Malignant glioma, grade 3-4 or 4

Interventions

Patients were randomised to either

- 1. Standard RT (60 Gy in 2 Gy fractions over 6 weeks)
- 2. Hypofractionated RT (34 Gy in 3,4 Gy fractions over 2 weeks)
- 3. 6 cycles of chemotherapy with TMZ (200 mg/m2 day 1-5 every 28 days)

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Temozolomide (Temodal®) (TMZ)

Primary outcome(s)

1. Survival

Key secondary outcome(s))

- 1. Quality of Life
- 2. Symptom control
- 3. Safety
- 4. Health resource utilization

Completion date

Eligibility

Key inclusion criteria

- 1. Age > 60
- 2. Performance Status (PS) 0-2 according to the WHO definition. Patients with a general condition corresponding to WHO 0-2, but due to physical handicap are graded as PS 3 or 4 can also be included.
- 3. Patients with histologically/cytologically confirmed glioma grade 3-4 or 4
- 4. Expected to tolerate all three treatment options
- 5. Life expectancy of at least 3 months
- 6. General organ function allowing chemotherapy as indicated by:
- 6.1. Neutrophiles > 1.5 x 109/l
- 6.2. Platelets > 100 x 109/l
- 6.3. Haemoglobin > 10 g/dl (100 g/l)
- 6.4. Serum creatinine and bilirubin < 1.5 times upper normal limit
- 6.5. Aspartate Aminotransferase (ASAT), alanine Aminotransferase (ALAT) < 3 times upper normal limit
- 7. No other medical condition likely to interfere with treatment or the assessment of its efficacy
- 8. Patient is on the lowest steroid dose, which gives optimal functional improvement
- 9. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Sex

All

Key exclusion criteria

- 1. Patients with other primary cancer, with the exception of radically treated squamous or basal cell carcinoma of the skin or other curatively treated malignancy without relapse 2 years after diagnosis
- 2. PS WHO grade 3-4, except for patients with a general condition corresponding to WHO 0-2, but due to physical handicap are graded as PS 3 or 4
- 3. Any other medical condition which, in the view of the investigator, is a contraindication to inclusion in the study
- 4. Chemotherapy, biological therapy, radiotherapy or immunotherapy given previously for brain tumour or within 3 years for other malignancy
- 5. Radiotherapy to the head, which would interfere with giving radiotherapy treatment for brain tumour

Date of first enrolment

01/02/2000

Date of final enrolment

31/12/2009

Locations



Austria

Denmark

France

Norway

Sweden

Switzerland

Türkiye

Study participating centre
Unit of Advanced Palliative Home Care
Linköping
Sweden
581 85

Sponsor information

Organisation

Nordic Clinical Brain Tumor Study group (Sweden)

Funder(s)

Funder type

Other

Funder Name

Nordic Clinical Brain Tumor Study group (Sweden)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created Date add	ed Peer reviewed	? Patient-facing?
Results article	results	01/09/2012	Yes	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/20	25 No	Yes